These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31701888)

  • 21. A Useful Map With Some Blind Spots Still: Neurofilament Light Protein Differentiating Behavioral Variant Frontotemporal Dementia From Psychiatric Disorders.
    Eratne D; Santillo AF
    Am J Geriatr Psychiatry; 2024 Aug; 32(8):1002-1003. PubMed ID: 38744614
    [No Abstract]   [Full Text] [Related]  

  • 22. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration.
    Goossens J; Bjerke M; Van Mossevelde S; Van den Bossche T; Goeman J; De Vil B; Sieben A; Martin JJ; Cras P; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2018 Mar; 10(1):31. PubMed ID: 29559004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.
    Meeter LHH; Vijverberg EG; Del Campo M; Rozemuller AJM; Donker Kaat L; de Jong FJ; van der Flier WM; Teunissen CE; van Swieten JC; Pijnenburg YAL
    Neurology; 2018 Apr; 90(14):e1231-e1239. PubMed ID: 29514947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Berger T; Stüve O
    Neurology; 2019 Mar; 92(10):451-452. PubMed ID: 30737335
    [No Abstract]   [Full Text] [Related]  

  • 25. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The multifaceted role of neurofilament light chain protein: emerging opportunities in primary psychiatric conditions.
    Bavato F; Seifritz E; Quednow BB
    Brain; 2024 Jan; 147(1):e5-e6. PubMed ID: 37615305
    [No Abstract]   [Full Text] [Related]  

  • 27. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
    Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
    Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood neurofilament light chain at the doorstep of clinical application.
    Leppert D; Kuhle J
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e599. PubMed ID: 31516914
    [No Abstract]   [Full Text] [Related]  

  • 29. Neurofilament makes light of MS treatment monitoring.
    Fyfe I
    Nat Rev Neurol; 2019 Apr; 15(4):188. PubMed ID: 30804512
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum neurofilament light as a prognostic marker for MS disability: Are we there yet?
    van Kempen ZLE; Kryscio RJ; Dalla Costa G
    Neurology; 2020 Jun; 94(23):1013-1014. PubMed ID: 32434864
    [No Abstract]   [Full Text] [Related]  

  • 31. The prognostic value of neurofilament light chain in serum.
    Sellebjerg F; Magyari M
    Lancet Neurol; 2022 Mar; 21(3):207-208. PubMed ID: 35182499
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Goldschmidt C; Fox RJ
    Neurology; 2021 Nov; 97(19):887-888. PubMed ID: 34504029
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High serum neurofilament light chain predicts a worse fate in early parkinsonism.
    Akhtar RS; Mano T
    Neurology; 2019 Mar; 92(13):595-596. PubMed ID: 30814326
    [No Abstract]   [Full Text] [Related]  

  • 36. CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Khalil M; Salzer J
    Neurology; 2016 Sep; 87(11):1068-9. PubMed ID: 27521432
    [No Abstract]   [Full Text] [Related]  

  • 37. Neurofilament as a biomarker - are we there yet?
    Hemingway C
    Eur J Paediatr Neurol; 2023 Jul; 45():A5. PubMed ID: 37423817
    [No Abstract]   [Full Text] [Related]  

  • 38. Is CSF neurofilament light chain measurement relevant for MS?
    Matsui M
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32928895
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum neurofilament light chain and small fiber neuropathy: Every cloud has a silver lining.
    Plantone D; Primiano G
    Eur J Neurol; 2024 May; 31(5):e16244. PubMed ID: 38344915
    [No Abstract]   [Full Text] [Related]  

  • 40. Reader response: Serum neurofilament light is sensitive to active cerebral small vessel disease.
    Schreiber S; Scheumann V; Perosa V; Vielhaber S; Assmann A
    Neurology; 2018 Jun; 90(24):1126. PubMed ID: 29891580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.